Carole is an infectious disease physician with 25 years of development experience in academics, large pharma, and biotech companies. She is currently a clinical development consultant for antibiotic biotech companies and head of clinical development at Antabio. Her experience includes overseeing preclinical and clinical development, regulatory approvals, and launch of multiple compounds. She has extensive experience in-licensing and out-licensing anti-infective assets. Her responsibilities at Merck included leadership of multiple global program teams and later as VP in the Infectious Disease Franchise overseeing the development strategy for all programs in the Franchise. She was also CMO at several successful biotech companies, including Novexel (acquired by Astra Zeneca), Vitae (acquired by Allergan), Arixa (acquired by Pfizer), and Scynexis (successful IPO). Notably, Carole led the development of caspofungin from Phase 1 through worldwide regulatory approvals and launches for multiple indications. At Novexel, she led the development of ceftazidime-avibactam from initiation of clinical development through successful Phase 2B studies. She designed innovative development approaches and introduced novel study designs for both programs thereby demonstrating the strengths of each drug early in development.
She is currently a scientific advisor for CARB-X and has served on Scientific Advisory Boards. She has published > 30 research papers and reviews in peer reviewed journals. She received her medical degree at Jefferson Medical College in Philadelphia and her internal medicine residency and Infectious Disease Fellowship at the University of Virginia in Charlottesville. Prior to her move to Industry she was on faculty at the University of Virginia in Infectious Diseases and Internal Medicine.